Of 27 NMES, ONLY 2 WERE BIOLOGICS
Biologic new molecular entities approvals are nothing to write home about
By Mari Serebrov
To say 2013 was not a banner year for novel biologic approvals would be an understatement. The FDA approved 27 new molecular entities (NMEs) last year, but only two were biologics – Gazyva (obinutuzumab) and Kadcyla (ado-trastuzumab emtansine). Both were developed by the same company, Roche AG subsidiary Genentech Inc.